BridgeBio Pharma BBIO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost of license, services, and royalty revenue | $10.3M— | $4.4M— | $9.1M— | —— | —— | |
| License and services revenue | $4.42M-94.5% | $2.88M+1.8% | $8.31M+204% | $31M+2,285% | $79.69M-38.9% | |
| Percentage of capitalized property and equipment by Geography | ||||||
| Canada | 54.1%— | 51.6%+6.9pp | —— | —— | —— | |
| U.S. | 41.5%— | 44.2%-7.4pp | —— | —— | —— | |
| Percentage of concentration risk by Geography | ||||||
| APAC | 1.1%-1.2pp | —— | 2.7%-82.3pp | 3.6%-62.5pp | 2.3%-31.2pp | |
| EMEA | 6%-60.1pp | —— | 7.7%-5.5pp | 31.7%+15.0pp | 66.1%+4.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BridgeBio Pharma break its business down?
- BridgeBio Pharma (BBIO) reports revenue by product across 2 parts — Cost of license, services, and royalty revenue and License and services revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does BridgeBio Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BridgeBio Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
